First Patient Dosed in Phase I/II Trial of Renal Cancer Imaging Product in Japan
17 août 2020 20h00 HE
|
Telix Pharmaceuticals Limited
TOKYO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that...
Telix Japan Signs MOU with ATOX to Use IRE ELiT 68Ge/68Ga-Generator for Phase I Study of Prostate Cancer Diagnostic Imaging
27 juil. 2020 02h21 HE
|
Telix Pharmaceuticals Limited
TOKYO, July 27, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce it has...
Telix Pharmaceuticals submits European marketing authorisation application for prostate cancer imaging product
30 avr. 2020 20h14 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has submitted a marketing...
Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer
29 oct. 2019 19h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ADELAIDE, Australia, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) has today announced that Telix and AusHealth have entered into a collaboration...
Telix Pharmaceuticals and GE Healthcare: Maximising 68Ga Supply for Prostate Cancer Imaging
13 oct. 2019 19h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX, “Telix”, the “Company”) a clinical-stage biopharmaceutical company focused on the development of...
Telixが日本で腎臓がん用画像診断薬の臨床治験を開始
29 août 2019 20h00 HE
|
Telix Pharmaceuticals Limited
メルボルン, オーストラリア および京都, 日本, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals...
Telix Pharmaceuticals to Launch Japanese Renal Cancer Imaging Study
29 août 2019 20h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the...
Telix Pharmaceuticals and GenesisCare Commence ENHANCING Prostate Cancer Clinical Study
07 août 2019 20h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and SYDNEY, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on...
Telix Pharmaceuticals and German Cancer Research Center (DKFZ) Enter into Collaboration and Option Agreement for Image-Guided Prostate Surgery
04 août 2019 20h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and HEIDELBERG, Germany, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused...
Telix Pharmaceuticals e Grupo RPH firmam Contrato de Manufatura e Distribuição para a LATAM
02 juil. 2019 20h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Austrália e PORTO ALEGRE, Brasil, July 02, 2019 (GLOBE NEWSWIRE) -- A Telix Pharmaceuticals Limited (ASX.TLX) ( “Telix”, a “Empresa”), uma empresa biofarmacêutica de fase clínica...